These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

5001 related items for PubMed ID: 508607

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R, Wybran J, Epstein W.
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [Abstract] [Full Text] [Related]

  • 3. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N, Crowther D.
    Dev Biol Stand; 1975 Mar; 38():449-53. PubMed ID: 608536
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM, Macher E, Bröcker EB, Suciu S, Steerenberg PA, Jung E, Rümke P.
    Dermatology; 1996 Mar; 193(2):105-9. PubMed ID: 8884144
    [Abstract] [Full Text] [Related]

  • 5. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
    Thatcher N, Swindell R, Crowther D.
    Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
    [Abstract] [Full Text] [Related]

  • 6. Immunological changes in cancer patients receiving BCG.
    Cochran AJ, Mackie RM, Jackson AM, Ogg LJ, Ross CE.
    Dev Biol Stand; 1979 Jan; 38():441-8. PubMed ID: 608535
    [Abstract] [Full Text] [Related]

  • 7. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA, Rapp HJ.
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [Abstract] [Full Text] [Related]

  • 8. The use of oral BCG in the treatment or metastatic malignant melanoma.
    Pritchard KI, Cowan DH, Baker MA, Osoba D, Phillips RA, Clark DA.
    Med Pediatr Oncol; 1976 May; 2(2):173-81. PubMed ID: 785199
    [Abstract] [Full Text] [Related]

  • 9. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB.
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.
    Thatcher N, Swindell R, Crowther D.
    Clin Exp Immunol; 1979 Jun; 36(3):456-64. PubMed ID: 487647
    [Abstract] [Full Text] [Related]

  • 12. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ, Hadden EM, Kaplan MH, Pinsky CM, Armstrong D, Hadden JW.
    Clin Bull; 1977 Jun; 7(2):63-9. PubMed ID: 902403
    [No Abstract] [Full Text] [Related]

  • 13. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN, Iavorskiĭ VV, Kadagidze ZG, Malaev SG, Kupin VI.
    Vopr Onkol; 1977 Jun; 23(8):27-33. PubMed ID: 906404
    [Abstract] [Full Text] [Related]

  • 14. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS, Peters M.
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [Abstract] [Full Text] [Related]

  • 15. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS, Mastrangelo MJ, Sulit H, Chee D, Yarbro JW, Prehn LM, Prehn RT.
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract] [Full Text] [Related]

  • 16. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V, Knopf B.
    Arch Geschwulstforsch; 1981 Dec; 51(6):493-6. PubMed ID: 7332442
    [Abstract] [Full Text] [Related]

  • 17. Results of administering B.C.G. to patients with melanoma.
    Grant RM, Mackie R, Cochran AJ, Murray EL, Hoyle D, Ross C.
    Lancet; 1974 Nov 09; 2(7889):1096-100. PubMed ID: 4139404
    [No Abstract] [Full Text] [Related]

  • 18. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH, Deutschmann EM, Schultheis W, Deicher H.
    Dev Biol Stand; 1974 Nov 09; 38():537-40. PubMed ID: 344106
    [Abstract] [Full Text] [Related]

  • 19. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
    Gutterman J, Mavligit G, McBride C, Frei E, Hersh EM.
    Cancer; 1973 Aug 09; 32(2):321-7. PubMed ID: 4722915
    [No Abstract] [Full Text] [Related]

  • 20. Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy.
    Lui VK, Karpuchas J, Dent PB, McCulloch PB, Blajchman MA.
    Br J Cancer; 1975 Sep 09; 32(3):323-30. PubMed ID: 1233077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 251.